---
title: "ATRA.US (ATRA.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/ATRA.US/news.md"
symbol: "ATRA.US"
name: "ATRA.US"
parent: "https://longbridge.com/zh-CN/quote/ATRA.US.md"
datetime: "2026-03-13T03:03:51.385Z"
locales:
  - [en](https://longbridge.com/en/quote/ATRA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ATRA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ATRA.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/ATRA.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/ATRA.US/news.md)


# ATRA.US (ATRA.US) — 相关新闻

### [07:58 ETPierre Fabre Pharmaceuticals Announces Type A Meeting Agreed with U.S. Food and Drug Administration (FDA) for Tabelecleucel Biologic License Application (BLA)](https://longbridge.com/zh-CN/news/278878228.md)
*2026-03-12T11:58:55.000Z*
> Pierre Fabre Pharmaceuticals has announced that the U.S. FDA has agreed to a Type A meeting regarding the biologic licen

### [Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel | ATRA Stock News](https://longbridge.com/zh-CN/news/278879649.md)
*2026-03-12T04:05:41.000Z*
> Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel | ATRA Stock News

### [](https://longbridge.com/zh-CN/news/277670477.md)
*2026-03-03T19:34:57.000Z*
> Atara Biotherapeutics shares are trading higher after the company announced its partner Pierre Fabre Pharmaceuticals has

### [Atara Biotherapeutics partner seeks Type A FDA meeting on tabelecleucel following CRL](https://longbridge.com/zh-CN/news/277632207.md)
*2026-03-03T13:43:01.000Z*
> Atara Biotherapeutics' partner, Pierre Fabre, has requested a Type A meeting with the FDA to discuss the Complete Respon

### [Genetix Biotherapeutics Inc In 2026, Genetix Is Doubling Manufacturing Capacity, Enabling Substantial Increase In Annual Patients Treated](https://longbridge.com/zh-CN/news/277471315.md)
*2026-03-02T13:18:15.000Z*
### [Regeneron Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors](https://longbridge.com/zh-CN/news/277101836.md)
*2026-02-26T21:43:59.000Z*
> Regeneron Pharmaceuticals Inc. (REGN) shares fell 1.72% to $770.79 on Thursday, underperforming compared to competitors.

### [Atara jumps amid report on FDA’s U-turn on cell therapy](https://longbridge.com/zh-CN/news/276930586.md)
*2026-02-25T19:32:19.000Z*
> Shares of Atara Biotherapeutics (ATRA) rose following a report that the FDA may reconsider its rejection of the cell the